Browse our 1,000+ Publications​

Latest Publications

Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL

Short N, et al.
Blood Cancer Journal
October 2025
Authors and Affiliates
Nicholas J. Short 1,5✉, Elias Jabbour 1,5, Walid Macaron1,2,5, Nitin Jain1 , Fadi G. Haddad 1 , Sanam Loghavi 3 , Tapan M. Kadia 1 , Partow Kebriaei4 , Eitan Kugler1 , Jairo Matthews1 , Rebecca Garris1 , Farhad Ravandi 1 and Hagop Kantarjian 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4 Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 These authors contributed equally: Nicholas J. Short, Elias Jabbour, Walid Macaron.

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study

Bahlis N, et al.
Leukemia & Lymphoma
October 2025
Authors and Affiliates
Nizar J. Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A. Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson & Thierry Facon a Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; bBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA; c Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; dVejle Hospital, University of Southern Denmark, Vejle, Denmark; e Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy; f Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland; gClínica Medica São Germano, São Paulo, Brazil; hAbteilung für Innere Medizin II, Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Tübingen, Germany; i Hospital São Rafael, Instituto D’Or de Pesquisa e Ensino and Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia-HUPES-UFBA, Salvador, Brazil; j Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; k Université de Toulouse, CHU de Toulouse, Service d’Hématologie, Toulouse, France; l Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; mZNA Stuivenberg, Antwerp, Belgium; nEvangelismos Hospital, Athens, Greece; o Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; pDepartment of Medicine, Korea University, Seoul, South Korea; qAlbert Schweitzer Hospital, Dordrecht, The Netherlands; r Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; s Johnson & Johnson, Washington, PA, USA; t Johnson & Johnson, Raritan, NJ, USA; u Johnson & Johnson, Shanghai, China; v University of Lille, CHU Lille, Lille, France

Safety and efficacy of a dexamethasone-sparing regimenwith daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

Manier S, et al.
Lancet Oncology
October 2025
Authors and Affiliates
Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Borhane Slama, Lionel Karlin, Frédéric Orsini Piocelle, Mamoun Dib, Laurence Sanhes, Pierre Morel, Abderazzak El Yamani, Mourad Tiab, Reza Tabrizi, Valentine Richez, Laurent Garderet, Bruno Royer, Benoit Bareau, Clara Mariette, Emmanuel Fleck, Daniela Robu, Claire Calmettes, Sophie Rigaudeau, Hélène Demarquette, Laurent Frenzel, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Noémie Bigot, Aurore Perrot, Jill Corre, Jean-Yves Mary, Hervé Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon Department of Hematology, University Hospital of Lille, Lille, France (Prof S Manier MD PhD, Prof T Facon MD), Department of Biostatistics and Epidemiology (Prof J Lambert MD PhD, N Bigot MSc, J-Y Mary PhD), and Department of Hematology (B Royer MD, Prof B Arnulf MD PhD), University Hospital of SaintLouis, Paris, France; Department of Hematology, University Hospital of Bordeaux, Bordeaux, France (C Hulin MD); Department of Hematology, University Hospital of Caen Normandie, Caen, France (M Macro MD); Department of Hematology, Le Mans Hospital, Le Mans, France (K Laribi MD); Department of Hematology, Côte Basque Hospital, Bayonne, France (C Araujo MD); Department of Hematology, Metropole Savoie Hospital, Chambéry, France (G M Pica MD); Department of Hematology, University Hospital of Nantes, Nantes, France (Prof C Touzeau MD PhD, Prof P Moreau MD PhD); Department of Hematology, Bretagne-Atlantique Hospital, Vannes, France (P Godmer MD); Department of Hematology, Avignon Hospital, France (B Slama MD); Department of Hematology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France (L Karlin MD); Department of Hematology, Annecy Genevois Hospital, Annecy, France (F Orsini Piocelle MD); Department of Hematology, University Hospital of Angers, Angers, France (M Dib MD); Department of Hematology, Perpignan Hospital, Perpignan, France (L Sanhes MD); Department of Hematology, University Hospital of Amiens, Amiens, France (Prof P Morel MD PhD); Department of Hematology, Simone Veil Hospital, Blois, France (A El Yamani MD); Department of Hematology, La Roche-sur-Yon Hospital, La Roche-sur-Yon, France (M Tiab MD); Department of Hematology, Mont-De-Marsan Hospital, Mont-De-Marsan, France (R Tabrizi MD); Department of Hematology, University Hospital of Nice, Nice, France (V Richez MD); Department of Hematology, University Hospital of Pitié Salpetriere, Paris, France (L Garderet MD PhD); Department of Hematology, Les Hôpitaux Privés Rennais, Cesson Sévigné, France (B Bareau MD); Department of Hematology, University Hospital of Grenoble, Grenoble, France (C Mariette MD); Department of Hematology, La Rochelle Ré Aunis Hospital, La Rochelle, France (E Fleck MD); Department of Hematology, Lens Hospital, Lens, France (D Robu MD); Department ofHematology, Périgueux Hospital, Périgueux, France (C Calmettes MD); Department of Hématologie, Versaille Hospital, Le ChesnayRocquencourt, France (S Rigaudeau MD); Department of Hématologie, Dunkerque Hospital, Dunkerque, France (H Demarquette MD); Department of Hematology, University Hospital of Necker, Paris, France (L Frenzel MD PhD); Department of Hematology, University Hospital of Rennes, Rennes, France (Prof O Decaux MD PhD); Department of Hematology, Sorbonne University, SaintAntoine Hospital, Paris, France (Prof M Mohty MD PhD); Department of Hematology (Prof A Perrot MD PhD) and Unit for Genomics in Myeloma (Prof J Corre PharmaD PhD, Prof H Avet-Loiseau MD PhD), University Hospital of Toulouse–Oncopole, Toulouse, France; Department of Hematology, University Hospital of Poitiers, Poitiers, France (Prof X Leleu MD PhD)

Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure‑Response Analysis of the DREAMM‑8 Study

Hanafin P, et al.
Targeted Oncology
September 2025
Authors and Affiliates
Patrick Hanafn1  · Yu Liu Ho1  · Theodoros Papathanasiou2  · Giulia Fulci3  · Neal Sule1  · Brandon E Kremer1  · Geraldine Ferron‑Brady1 1 GSK, 1250 S Collegeville Rd, Collegeville, PA 19426, USA 2 GSK, Baar, Switzerland 3 GSK, Waltham, MA, USA

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

Gautam S, et al.
J Manag Care Spec Pharm
September 2025
Authors and Affiliates
Santosh Gautam, PhD; Laura Morrison, MPH; Philippe Thompson-Leduc, MSc; Bronwyn Moore, BA; Gordon Wong, BA; Brian Macomson, PharmD; Vipin Khare, MD; Niodita Gupta-Werner, MD, MPH, PhD; Rohan Medhekar, PhD Johnson & Johnson, Horsham, PA (Gautam, Macomson, Khare, Gupta-Werner, Medhekar); Analysis Group ULC, Montréal, QC, Canada (Morrison, Thompson-Leduc, Moore, Wong)

HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis

Zhang BC, et al.
EBio Medicine
September 2025
Authors and Affiliates
Brian C. Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik Yusko, Damon May, Daniel Mattox, Eva Dawin, Lisa Ann Gerdes, Florence Bucciarelli, Lisa Revie, Gisela Antony, Sven Jarius, Christiane Seidel, Makbule Senel, Stefan Bittner, Felix Luessi, Joachim Havla, Matthias Knop, Manuel A. Friese, Susanne Rothacher, Anke Salmen, Fumie Hayashi, Roland Henry, Stacy Caillier, Adam Santaniello, University of California San Francisco MS-EPIC Team, German Competence Network Multiple Sclerosis (KKNMS), Maria Seipelt, Christoph Heesen, Sandra Nischwitz, Antonios Bayas, Hayrettin Tumani, Florian Then Bergh, Gerd Meyer zu Hörste, Tania Kümpfel, Catharina C. Gross, Brigitte Wildemann, Martin Kerschensteiner, Ralf Gold, Sven G. Meuth, Frauke Zipp, Bruce A. C. Cree, Jorge Oksenberg, Michael R. Wilson, Stephen L. Hauser, Scott S. Zamvil, Luisa Klotz, Roland Liblau.

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Yoroidaka T, et al.
Haematologica
September 2025
Authors and Affiliates
Takeshi Yoroidaka,1* Hiroyuki Takamatsu,1* Ryota Urushihara,2 Mitsuhiro Itagaki,3 Satoshi Yoshihara,4 Kota Sato,5 Naoki Takezako,6 Shuji Ozaki,7 Kazuhito Suzuki,8 Kentaro Kohno,9 Tsuyoshi Muta,3 Morio Matsumoto,10 Yasushi Terasaki,11 Takeshi Yamashita,12 Shin-ichi Fuchida,13 Jun Sakamoto,14 Tadao Ishida,5 Kenshi Suzuki,5 Hirokazu Murakami,15 Brian G. M. Durie16 and Kazuyuki Shimizu17 1 Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; 2Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan; 3Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; 4Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya, Japan; 5Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; 6Department of Hematology, Nerima Hikarigaoka Hospital, Tokyo, Japan; 7 Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan; 8Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; 9Department of Hematology, Japan Community Healthcare Organization Kyusyu Hospital, Kitakyushu, Japan; 10Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan; 11Division of Hematology, Toyama City Hospital, Toyama, Japan; 12Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; 13Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan; 14Bio Medical Laboratories (BML), INC., Kawagoe, Japan; 15Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi, Japan; 16Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA and 17Department of Hematology, Higashi Nagoya National Hospital, Nagoya, Japan

Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis

Vianna P, et al.
Blood
July 2025
Authors and Affiliates
Pedro Vianna1,2,3, Rajshekar Chakraborty4, Shahrier Hossain2, Divaya Bhutani4, Shannon Miller2, Annemarie Rossi2, Sarah A. M. Cuddy3,5, Rodney H. Falk3,5, Suzanne Lentzsch4, Jacob Laubach2,3, Giada Bianchi1,2,3* 1Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Harvard Medical School, Boston, MA; 4Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, 5Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Hungria V, et al.
Lancet Oncology
July 2025
Authors and Affiliates
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, on behalf of the DREAMM-7 study investigators Clinica São Germano, São Paulo, Brazil (V Hungria MD); Medical University of Łódź, Łódź, Poland (Prof P Robak MD); Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland (Prof M Hus MD, M Mielnik MD); Gorodskaya Klinicheskaya Bol’nitsa Im Sp Botkina, Moscow, Russia (V Zherebtsova MD); Royal North Shore Hospital, Sydney, NSW, Australia (Prof C Ward MD); Royal Prince Alfred Hospital, Camperdown, NSW, Australia (Prof P J Ho MBBS); University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic (Prof R Hájek MD); Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea (Prof K Kim MD); Medical University of Silesia, Katowice, Poland (Prof S Grosicki MD); Pindara Private Hospital, Gold Coast, QLD, Australia (H Sia MBBS); Liverpool Hospital, Sydney, NSW, Australia (A Bryant PhD); Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil (Prof M Pitombeira de Lacerda MD); Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil (G A Martinez MD); Institut Català d’Oncologia- L’Hospitalet L.-Barcelona, Barcelona, Spain (A Sureda Balarí MD); Cross Cancer Institute, Edmonton, AB, Canada (I Sandhu MD); Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST IRCCS, Meldola, Forlì-Cesena, Italy (C Cerchione MD); Christchurch Hospital, Christchurch, New Zealand (P Ganly PhD); School of Medicine, National and Kapodistrian University of Athens, Athens, Greece (Prof M A Dimopoulos MD); Korea University, Seoul, South Korea (Prof M A Dimopoulos); The First Affiliated Hospital of Soochow University, Jiangsu, China (Prof C Fu MD); University Hospitals of Leicester NHS Trust, Leicester, UK (M Garg MD); University of Kansas Cancer Center, Fairway, KS, USA (A-O Abdallah MD); Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M E Gatt MD); Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain (A Oriol Rocafiguera MD); Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (Prof M Cavo MD); Rocky Mountain Cancer Centers— Denver—Midtown, Denver, CO, USA (R Rifkin MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); GSK, Collegeville, PA, USA (J Ficek PhD, A Mantero PhD, N Pirooz MHA, S Varghese MBBS, R Rogers MS, S Roy-Ghanta MD, P Mukhopadhyay PhD, J Opalinska MD); GSK, London, UK (J Lee PhD, L Eccersley PhD); GSK, Stevenage, UK (A McKeown PhD); GSK, Mississauga, ON, Canada (H Baig BS); GSK, Chicago, IL, USA (J Nielsen PhD); Instituto de Investigación Biomédica de Salamanca, Hospital Universitario de Salamanca– IBSAL–CIC–Ciberonc, Salamanca, Spain (M-V Mateos MD)